Eli Lilly: 4 Reasons Investors Shouldn't Miss This Opportunity

Eli Lilly and Company TodayLLYEli Lilly and Company$797.17 -2.73 (-0.34%) 52-Week Range$612.70▼$972.53Dividend Yield0.75%P/E Ratio86.18Price Target$1,002.22Add to WatchlistEli Lilly & Co. NYSE: LLY is a major global pharmaceutical company in the medical sector. The company made headlines with its dominant GLP-1 drug, Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. While there are many potential contenders in clinical trials, the current GLP-1 market is a duopoly that Eli Lilly d ...